No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Ocrevus is a Central Nervous System (CNS) drug developed by Genentech, a member of the Roche Group, for the treatment of multiple sclerosis (MS). It is the first and only approved therapy for both relapsing and primary progressive forms of MS. Ocrevus is a monoclonal antibody that works by targeting a protein called CD20, which is found on the surface of certain immune cells. This helps to reduce the number of these cells, which can cause inflammation and damage to the nerves in MS patients.
The CNS drug market is a rapidly growing sector, with a range of treatments available for various neurological conditions. Ocrevus is one of the most widely used drugs in this market, and is used to treat MS, a condition that affects millions of people worldwide. Other drugs in this market include Tecfidera, Gilenya, and Aubagio, which are used to treat MS, as well as drugs for Parkinson's disease, Alzheimer's disease, and epilepsy.
Companies in the Ocrevus market include Genentech, Novartis, Biogen, Merck, and Sanofi. Show Less Read more
